Objective:

To report on the efficacy of tislelizumab and bevacizumab in a patient with primary malignant pericardial mesothelioma (PMPM).

Approach:

Key Findings:

• The patient showed significant relief from symptoms of chest tightness and breathlessness.
• Imaging assessments indicated stable disease throughout the treatment.
• No severe adverse reactions leading to mortality were reported, only grade II bone marrow suppression.

Interpretation:

Limitations:

• Only one patient was included in the study.
• The small number of cases limits generalizability.
• Uncertainty remains regarding the applicability of this treatment to all PMPM patients.

Conclusion:

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.